Literature DB >> 20823234

Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia.

Joanna Pancewicz1, John M Taylor, Abhik Datta, Hicham H Baydoun, Thomas A Waldmann, Olivier Hermine, Christophe Nicot.   

Abstract

The Notch signaling pathway plays an important role in cellular proliferation, differentiation, and apoptosis. Unregulated activation of Notch signaling can result in excessive cellular proliferation and cancer. Human T-cell leukemia virus type 1 (HTLV-I) is the etiological agent of adult T-cell leukemia (ATL). The disease has a dismal prognosis and is invariably fatal. In this study, we report a high frequency of constitutively activated Notch in ATL patients. We found activating mutations in Notch in more than 30% of ATL patients. These activating mutations are phenotypically different from those previously reported in T-ALL leukemias and may represent polymorphisms for activated Notch in human cancers. Compared with the exclusive activating frameshift mutations in the proline, glutamic acid, serine, and threonine (PEST) domain in T-ALLs, those in ATLs have, in addition, single-substitution mutations in this domain leading to reduced CDC4/Fbw7-mediated degradation and stabilization of the intracellular cleaved form of Notch1 (ICN1). Finally, we demonstrated that inhibition of Notch signaling by γ-secretase inhibitors reduced tumor cell proliferation and tumor formation in ATL-engrafted mice. These data suggest that activated Notch may be important to ATL pathogenesis and reveal Notch1 as a target for therapeutic intervention in ATL patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20823234      PMCID: PMC2944748          DOI: 10.1073/pnas.1010722107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia.

Authors:  Steven M Chan; Andrew P Weng; Robert Tibshirani; Jon C Aster; Paul J Utz
Journal:  Blood       Date:  2007-03-15       Impact factor: 22.113

Review 2.  Mechanisms of tumor suppression by the SCF(Fbw7).

Authors:  Alex C Minella; Bruce E Clurman
Journal:  Cell Cycle       Date:  2005-10-27       Impact factor: 4.534

3.  Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.

Authors:  Stephen Breit; Martin Stanulla; Thomas Flohr; Martin Schrappe; Wolf-Dieter Ludwig; Gabriele Tolle; Margit Happich; Martina U Muckenthaler; Andreas E Kulozik
Journal:  Blood       Date:  2006-04-13       Impact factor: 22.113

Review 4.  Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia.

Authors:  Clemens Grabher; Harald von Boehmer; A Thomas Look
Journal:  Nat Rev Cancer       Date:  2006-05       Impact factor: 60.716

5.  Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia.

Authors:  Teresa Palomero; Maria Luisa Sulis; Maria Cortina; Pedro J Real; Kelly Barnes; Maria Ciofani; Esther Caparros; Jean Buteau; Kristy Brown; Sherrie L Perkins; Govind Bhagat; Archana M Agarwal; Giuseppe Basso; Mireia Castillo; Satoru Nagase; Carlos Cordon-Cardo; Ramon Parsons; Juan Carlos Zúñiga-Pflücker; Maria Dominguez; Adolfo A Ferrando
Journal:  Nat Med       Date:  2007-09-16       Impact factor: 53.440

Review 6.  FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation.

Authors:  Markus Welcker; Bruce E Clurman
Journal:  Nat Rev Cancer       Date:  2008-02       Impact factor: 60.716

7.  Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy.

Authors:  Yulia Nefedova; Daniel M Sullivan; Sophia C Bolick; William S Dalton; Dmitry I Gabrilovich
Journal:  Blood       Date:  2007-11-26       Impact factor: 22.113

8.  Engraftment of peripheral blood mononuclear cells from human T-lymphotropic virus type 1 carriers in NOD/SCID/gammac(null) (NOG) mice.

Authors:  Ichiro Takajo; Kazumi Umeki; Kazuhiro Morishita; Ikuo Yamamoto; Yoko Kubuki; Kinta Hatakeyama; Hiroaki Kataoka; Akihiko Okayama
Journal:  Int J Cancer       Date:  2007-11-15       Impact factor: 7.396

Review 9.  Mechanisms of transcription factor deregulation in lymphoid cell transformation.

Authors:  J O'Neil; A T Look
Journal:  Oncogene       Date:  2007-10-15       Impact factor: 9.867

10.  FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors.

Authors:  Jennifer O'Neil; Jonathan Grim; Peter Strack; Sudhir Rao; Deanne Tibbitts; Christopher Winter; James Hardwick; Markus Welcker; Jules P Meijerink; Rob Pieters; Giulio Draetta; Rosalie Sears; Bruce E Clurman; A Thomas Look
Journal:  J Exp Med       Date:  2007-07-23       Impact factor: 14.307

View more
  50 in total

1.  Human T-lymphotropic type 1 virus p30 inhibits homologous recombination and favors unfaithful DNA repair.

Authors:  Hicham H Baydoun; Joanna Pancewicz; Christophe Nicot
Journal:  Blood       Date:  2011-03-22       Impact factor: 22.113

Review 2.  Crosstalk between Nrf2 and Notch signaling.

Authors:  Nobunao Wakabayashi; Dionysios V Chartoumpekis; Thomas W Kensler
Journal:  Free Radic Biol Med       Date:  2015-05-21       Impact factor: 7.376

3.  miR-28-3p is a cellular restriction factor that inhibits human T cell leukemia virus, type 1 (HTLV-1) replication and virus infection.

Authors:  Xue Tao Bai; Christophe Nicot
Journal:  J Biol Chem       Date:  2015-01-07       Impact factor: 5.157

4.  Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia patients.

Authors:  Chien-Hung Yeh; Marcia Bellon; Joanna Pancewicz-Wojtkiewicz; Christophe Nicot
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-31       Impact factor: 11.205

5.  A Notch1-neuregulin1 autocrine signaling loop contributes to melanoma growth.

Authors:  K Zhang; P Wong; L Zhang; B Jacobs; E C Borden; J C Aster; B Bedogni
Journal:  Oncogene       Date:  2012-01-16       Impact factor: 9.867

6.  Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study.

Authors:  Maryam Fouladi; Clinton F Stewart; James Olson; Lars M Wagner; Arzu Onar-Thomas; Mehmet Kocak; Roger J Packer; Stewart Goldman; Sridharan Gururangan; Amar Gajjar; Tim Demuth; Larry E Kun; James M Boyett; Richard J Gilbertson
Journal:  J Clin Oncol       Date:  2011-08-08       Impact factor: 44.544

7.  FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.

Authors:  Natalina E Elliott; Susan M Cleveland; Victor Grann; John Janik; Thomas A Waldmann; Utpal P Davé
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

8.  PA28γ is a novel corepressor of HTLV-1 replication and controls viral latency.

Authors:  Nga Ling Ko; John M Taylor; Marcia Bellon; Xue Tao Bai; Sergey P Shevtsov; Miroslav Dundr; Christophe Nicot
Journal:  Blood       Date:  2012-10-26       Impact factor: 22.113

9.  NK cells prevent T cell lymphoma development in T cell receptor-transgenic mice.

Authors:  Sigrid Dubois; Lionel Feigenbaum; Thomas A Waldmann; Jürgen R Müller
Journal:  Cell Immunol       Date:  2020-02-27       Impact factor: 4.868

10.  Constitutive activation of Pim1 kinase is a therapeutic target for adult T-cell leukemia.

Authors:  Marcia Bellon; Ling Lu; Christophe Nicot
Journal:  Blood       Date:  2016-01-26       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.